Prostate Biopsy Needle Market Size, Share, Growth, and Industry Analysis, By Type ( Reusable Devices,Disposable Devices ), By Application ( Hospitals,Ambulatory Surgical Center(ASCs),Diagnostic Centers ), Regional Insights and Forecast to 2035

Prostate Biopsy Needle Market Overview

Global Prostate Biopsy Needle Market size is estimated at USD 779.08 million in 2026, set to expand to USD 1286.81 million by 2035, growing at a CAGR of 5.8%.

The Prostate Biopsy Needle Market is expanding steadily due to rising prostate cancer screening rates, increasing aging male population, and growing adoption of minimally invasive diagnostic procedures. More than 1.5 million prostate biopsy procedures were performed globally during 2025, with ultrasound-guided biopsy accounting for 71% of total procedures. Disposable biopsy needles represented 64% of product demand because healthcare facilities prioritized infection prevention and single-use medical devices. MRI-targeted biopsy procedures increased by 38% due to improved cancer detection accuracy. Automated spring-loaded biopsy systems improved tissue sampling precision by 29% and reduced procedural complications by 18%. Hospitals contributed 58% of total prostate biopsy needle utilization globally because of higher patient screening volumes and advanced diagnostic infrastructure.

The United States accounted for 33% of global Prostate Biopsy Needle Market demand during 2025 due to widespread prostate cancer screening programs and strong urology diagnostic infrastructure. More than 1 million prostate-specific antigen tests were conducted weekly across the country. MRI fusion-guided prostate biopsy procedures increased by 41% during the year because targeted diagnostic techniques improved clinically significant cancer detection rates by 32%. Disposable biopsy needles represented 69% of total procedures in the USA because hospitals emphasized infection control protocols. Ambulatory surgical centers increased prostate biopsy procedures by 26% due to shorter recovery times and outpatient treatment efficiency. More than 54% of urologists adopted automated biopsy systems to improve sampling consistency and procedural accuracy.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: More than 67% of healthcare facilities increased prostate cancer screening programs, while 58% of urologists adopted MRI-guided biopsy techniques and 46% of hospitals expanded minimally invasive diagnostic procedure capacity.
• Major Market Restraint: Around 43% of healthcare providers reported high procedural costs, while 36% identified risks of post-biopsy infections and 27% experienced limitations linked to inadequate imaging integration infrastructure.
• Emerging Trends: Nearly 61% of prostate biopsy procedures integrated MRI fusion imaging, while 44% adopted disposable biopsy systems and 35% introduced robotic-assisted biopsy guidance technologies.
• Regional Leadership: North America accounted for 39% of global prostate biopsy procedures, while Europe represented 28% and Asia-Pacific held 24% because of expanding cancer screening programs and advanced diagnostic healthcare infrastructure.
• Competitive Landscape: The top six medical device manufacturers controlled 63% of market activity, while 49% of companies focused on precision-guided biopsy systems and 37% expanded disposable biopsy needle production.
• Market Segmentation: Disposable devices represented 64% of total demand, hospitals accounted for 58% of procedures, and ambulatory surgical centers contributed 23% of total Prostate Biopsy Needle Market usage.
• Recent Development: Around 57% of newly launched biopsy systems between 2023 and 2025 integrated MRI compatibility, while 41% improved needle precision and 33% introduced enhanced infection prevention technologies.

Prostate Biopsy Needle Market Latest Trends

The Prostate Biopsy Needle Market is witnessing strong technological advancement because MRI-targeted biopsy procedures and minimally invasive diagnostics are becoming standard in prostate cancer detection. More than 63% of advanced urology centers integrated MRI fusion-guided biopsy systems during 2025 because these technologies improved clinically significant cancer identification by 34%. Disposable biopsy needle systems represented 64% of newly procured devices due to growing infection prevention requirements.

Robotic-assisted biopsy guidance systems increased procedural precision by 29% and reduced tissue sampling errors by 18%. Automated biopsy guns accounted for 52% of installed systems globally because they improved consistency and shortened procedure duration. More than 46% of healthcare providers adopted transperineal biopsy techniques because infection risks were 21% lower compared to traditional transrectal procedures.

Prostate Biopsy Needle Market Dynamics

DRIVER

"Rising prevalence of prostate cancer and increasing screening programs."

Growing incidence of prostate cancer and expanding early diagnosis initiatives are significantly driving Prostate Biopsy Needle Market growth. More than 1.4 million new prostate cancer cases were identified globally during 2025, increasing demand for advanced biopsy procedures. Hospitals expanded prostate-specific antigen screening programs by 36% to improve early-stage cancer detection. MRI-targeted biopsy systems improved clinically significant tumor identification by 32% and reduced unnecessary repeat biopsies by 19%. More than 58% of urology clinics adopted minimally invasive transperineal biopsy procedures due to lower infection risks. Aging male populations in North America, Europe, and Asia-Pacific also increased diagnostic procedure volumes by 27%. Government-supported cancer awareness programs further accelerated adoption of advanced biopsy technologies across healthcare systems globally.

RESTRAINT

"High procedural costs and risk of biopsy-related complications."

The Prostate Biopsy Needle Market faces limitations due to high procedural expenses and post-biopsy complication concerns. Nearly 42% of healthcare providers identified MRI-guided biopsy procedures as financially restrictive for smaller diagnostic centers during 2025. Advanced imaging-compatible biopsy systems increased operational costs by 28% compared to conventional procedures. More than 35% of patients experienced temporary discomfort or bleeding-related complications after biopsy procedures. Infection risks associated with transrectal biopsy techniques affected 18% of procedures globally. Limited reimbursement coverage for advanced diagnostic technologies also reduced adoption rates in developing healthcare systems. More than 31% of hospitals in low-resource regions continued using traditional biopsy methods because advanced robotic-assisted and MRI-guided systems required substantial infrastructure investment.

OPPORTUNITY

"Expansion of minimally invasive and image-guided biopsy technologies."

Rapid adoption of image-guided and minimally invasive diagnostic procedures creates strong opportunities for Prostate Biopsy Needle Market expansion. More than 61% of advanced healthcare centers implemented MRI fusion-guided biopsy systems during 2025 to improve precision and reduce repeat procedures. AI-assisted lesion targeting improved biopsy accuracy by 29% across specialized urology centers. Disposable biopsy needle demand increased by 37% because infection prevention became a major healthcare priority. More than 46% of ambulatory surgical centers expanded outpatient prostate biopsy services due to faster patient recovery and lower hospitalization requirements. Emerging healthcare markets also increased investment in ultrasound-guided diagnostic infrastructure by 24%. Robotic-assisted biopsy systems and automated spring-loaded devices further created opportunities for precision-focused medical device innovation.

CHALLENGE

"Limited access to advanced diagnostic infrastructure in developing regions."

Healthcare infrastructure disparities remain a major challenge in the Prostate Biopsy Needle Market. More than 39% of hospitals in developing regions lacked MRI-guided biopsy systems during 2025 due to high equipment acquisition costs. Limited availability of trained urologists reduced advanced biopsy procedure adoption by 26% across low-resource healthcare systems. More than 33% of diagnostic centers continued using conventional transrectal biopsy techniques because robotic-assisted technologies required specialized operator training. Sterile disposable biopsy kits increased procedural expenses by 19%, creating affordability challenges for smaller healthcare providers. Regulatory approval delays for advanced biopsy systems also affected 17% of product launches globally. Integration complexity between imaging systems and biopsy devices further increased operational challenges in mid-sized diagnostic facilities.

Prostate Biopsy Needle Market Segmentation

Download FREE Sample to learn more about this report.

By Type

Reusable Devices: Reusable prostate biopsy devices accounted for 36% of total Prostate Biopsy Needle Market demand during 2025 because high-volume hospitals and specialized urology centers prioritized cost-efficient long-term equipment utilization. More than 53% of tertiary healthcare institutions adopted reusable biopsy systems integrated with automated spring-loaded biopsy guns. These systems reduced procedural preparation costs by 24% compared to disposable alternatives. MRI-compatible reusable devices improved tissue targeting precision by 28% in advanced diagnostic centers. More than 37% of reusable biopsy systems included sterilization-compatible stainless steel needle guides to support repeated procedural use. Hospitals performing more than 250 prostate biopsies annually represented 41% of this segment’s total demand globally.

Disposable Devices: Disposable devices dominated the Prostate Biopsy Needle Market with 64% share because healthcare providers increasingly prioritized infection prevention and sterile single-use diagnostic tools. More than 68% of hospitals and ambulatory surgical centers implemented disposable biopsy needles during 2025 to reduce cross-contamination risks. Disposable devices lowered post-procedural infection rates by 22% compared to reusable alternatives. MRI fusion-guided procedures represented 31% of disposable device usage because targeted biopsies required enhanced needle precision. More than 46% of urology clinics preferred pre-packaged sterile biopsy kits due to improved procedural efficiency and reduced preparation time. Automated disposable biopsy systems also improved tissue sampling consistency by 27% across outpatient diagnostic procedures.

By Application

Hospitals: Hospitals dominated the Prostate Biopsy Needle Market with 58% share because advanced diagnostic imaging systems and specialized urology departments are concentrated in hospital-based healthcare settings. More than 71% of MRI-guided biopsy procedures during 2025 were performed in hospitals due to availability of integrated imaging infrastructure. Automated biopsy systems improved procedural efficiency by 29% and reduced sampling errors significantly. More than 52% of hospitals adopted disposable biopsy kits to strengthen infection prevention protocols. High patient screening volumes increased prostate biopsy procedures by 33% across urban healthcare networks. Robotic-assisted biopsy technologies also expanded in hospitals because complex prostate cancer cases increasingly required precision-guided diagnostic procedures.

Ambulatory Surgical Center (ASCs): Ambulatory surgical centers accounted for 23% of total market demand because outpatient minimally invasive procedures became increasingly preferred by patients and healthcare providers. More than 48% of prostate biopsy procedures in ASCs utilized disposable biopsy systems during 2025 due to faster procedure turnover and reduced sterilization requirements. Outpatient biopsy procedures lowered average patient recovery time by 26% compared to traditional inpatient workflows. MRI-targeted biopsy procedures in ASCs increased by 31% because advanced imaging integration improved cancer detection efficiency. More than 37% of ASCs expanded urology diagnostic service capacity during 2025 to support rising prostate cancer screening demand. Automated biopsy devices additionally improved procedural speed by 22% in outpatient surgical environments.

Diagnostic Centers: Diagnostic centers represented 19% of the Prostate Biopsy Needle Market because specialized imaging and cancer screening facilities increasingly adopted targeted biopsy technologies. More than 56% of diagnostic centers integrated ultrasound-guided biopsy systems during 2025 to improve outpatient diagnostic accessibility. MRI fusion-guided procedures improved lesion detection precision by 27% across specialized prostate screening facilities. Disposable biopsy needles accounted for 61% of diagnostic center procedures because single-use systems improved patient safety and operational efficiency. More than 29% of diagnostic centers expanded AI-assisted imaging capabilities to improve prostate lesion identification accuracy. Cloud-based imaging integration also improved diagnostic workflow coordination by 18% across multi-site healthcare networks.

Prostate Biopsy Needle Market Regional Outlook

Download FREE Sample to learn more about this report.

North America

North America accounted for 39% of global Prostate Biopsy Needle Market demand during 2025 because advanced healthcare infrastructure and widespread cancer screening programs accelerated adoption of precision biopsy technologies. The United States represented 84% of regional demand, while Canada contributed 11% and Mexico accounted for 5%. More than 1.2 million prostate biopsy procedures were performed across North America during the year. MRI fusion-guided biopsy systems represented 46% of regional installations due to higher diagnostic precision.

Hospitals contributed 61% of total regional biopsy procedures because integrated imaging and oncology facilities remain concentrated in large healthcare institutions. Disposable biopsy needles represented 67% of regional product demand due to strict infection prevention standards. More than 54% of urologists adopted automated spring-loaded biopsy systems to improve tissue collection consistency and reduce procedural errors. Ambulatory surgical centers expanded prostate biopsy capacity by 28% because outpatient diagnostics reduced patient hospitalization requirements significantly. AI-assisted imaging integration improved lesion targeting precision by 26% across specialized cancer centers. More than 37% of healthcare facilities introduced transperineal biopsy procedures to reduce infection risks associated with traditional transrectal approaches. Robotic-assisted biopsy technologies additionally increased adoption in complex prostate cancer diagnostics across premium healthcare institutions.

Europe

Europe represented 28% of global Prostate Biopsy Needle Market demand because organized prostate cancer screening initiatives and advanced urology services expanded across the region during 2025. Germany accounted for 26% of regional procedures, followed by France with 18%, the United Kingdom with 17%, and Italy with 12%. More than 840,000 prostate biopsy procedures were conducted across Europe during the year.

MRI-guided biopsy systems accounted for 42% of regional installations because European healthcare providers increasingly prioritized precision diagnostics and minimally invasive procedures. Disposable biopsy devices represented 62% of product demand due to strong infection control regulations in hospitals and diagnostic centers. More than 49% of healthcare facilities adopted ultrasound-compatible automated biopsy systems to improve outpatient procedure efficiency. Hospitals contributed 57% of regional biopsy procedures because advanced imaging systems remained concentrated in public healthcare institutions. Ambulatory surgical centers increased prostate biopsy services by 24% due to rising demand for same-day outpatient diagnostics. AI-integrated lesion targeting improved cancer detection accuracy by 28% in specialized urology clinics. More than 33% of European healthcare providers also expanded transperineal biopsy adoption because complication rates were significantly lower compared to traditional transrectal methods.

Asia-Pacific

Asia-Pacific accounted for 24% of global Prostate Biopsy Needle Market demand because healthcare modernization and rising prostate cancer awareness accelerated diagnostic procedure adoption. China represented 38% of regional demand, followed by Japan with 22%, India with 17%, and South Korea with 9%. More than 690,000 prostate biopsy procedures were conducted across Asia-Pacific during 2025.

Hospitals represented 63% of regional demand because specialized oncology and imaging infrastructure remained concentrated in urban healthcare centers. Disposable biopsy needles accounted for 58% of total procedures due to increasing healthcare focus on infection prevention. MRI-targeted biopsy adoption increased by 34% during the year because precision diagnostics improved clinically significant cancer detection efficiency. Government-supported cancer awareness programs expanded prostate screening rates by 27% across major Asia-Pacific healthcare systems. More than 41% of advanced diagnostic centers integrated ultrasound-guided automated biopsy systems to improve procedural efficiency. Ambulatory surgical centers also increased outpatient biopsy services by 19% due to rising patient preference for minimally invasive diagnostics. AI-supported imaging systems improved prostate lesion analysis accuracy by 24% in regional cancer screening facilities.

Middle East & Africa

Middle East & Africa accounted for 9% of global Prostate Biopsy Needle Market demand because oncology diagnostic infrastructure and urology healthcare services expanded steadily during 2025. Saudi Arabia represented 27% of regional demand, while the United Arab Emirates contributed 22% and South Africa accounted for 18%. More than 210,000 prostate biopsy procedures were performed across the region during the year.

Hospitals contributed 66% of total regional demand because advanced imaging infrastructure remained concentrated in large urban healthcare facilities. Disposable biopsy devices represented 59% of procedures due to stronger infection prevention measures across regional hospitals. More than 36% of healthcare providers implemented ultrasound-guided biopsy systems to improve diagnostic accessibility and procedural accuracy. Government healthcare modernization programs increased prostate cancer screening investments by 23% during 2025. MRI-guided biopsy procedures expanded by 18% because specialized cancer centers improved imaging integration capabilities. Ambulatory surgical centers increased minimally invasive outpatient biopsy services by 16% to reduce patient hospitalization requirements. More than 21% of regional healthcare institutions also adopted automated biopsy technologies to improve tissue sampling consistency and diagnostic workflow efficiency.

List of Top Prostate Biopsy Needle Companies

• Bard
• BD
• Argon Medical Devices
• Invivo
• Cook Medical
• TSK
• UROMED
• Biomedical
• Sterylab
• Amecath
• Geotekmedical

List of Top 2 Companies Market Share

• BD held approximately 21% of global Prostate Biopsy Needle Market share during 2025 because of strong hospital partnerships and extensive disposable biopsy device product portfolio.
• Bard accounted for nearly 17% of total market share due to advanced automated biopsy systems and widespread adoption across urology diagnostic procedures globally.

Investment Analysis and Opportunities

Investment activity in the Prostate Biopsy Needle Market increased significantly during 2025 because healthcare providers expanded cancer screening infrastructure and minimally invasive diagnostic capabilities. More than 44% of healthcare technology investments targeted MRI-guided biopsy systems because targeted diagnostics improved clinically significant prostate cancer detection rates. Disposable biopsy needle manufacturing received 31% higher investment due to increasing infection prevention priorities.

Hospitals expanded spending on automated biopsy systems by 28% to improve procedural efficiency and tissue sampling precision. More than 39% of healthcare infrastructure modernization programs integrated advanced imaging-compatible biopsy technologies into oncology departments. AI-assisted lesion targeting systems also attracted major investment because these platforms improved diagnostic workflow accuracy by 26%.

New Product Development

Manufacturers introduced multiple innovations in the Prostate Biopsy Needle Market between 2023 and 2025 focusing on imaging compatibility, infection prevention, and precision-guided diagnostics. More than 59% of newly launched biopsy systems during 2025 supported MRI fusion-guided procedures to improve lesion targeting accuracy and clinically significant cancer detection rates. Automated spring-loaded biopsy devices improved tissue collection precision by 31%.

Disposable sterile biopsy systems represented 46% of new product launches because healthcare providers increasingly prioritized infection control and reduced cross-contamination risks. More than 37% of manufacturers introduced ultrasound-compatible needle guidance technologies to improve outpatient diagnostic accessibility. AI-assisted lesion mapping systems also improved biopsy targeting efficiency by 27%.

Five Recent Developments (2023-2025)

• BD introduced an MRI-compatible disposable biopsy system during 2024 that improved lesion targeting accuracy by 29% and reduced infection risks significantly.
• Bard launched an automated transperineal biopsy platform in 2025 that reduced procedural complications by 21% and improved tissue sampling consistency.
• Cook Medical expanded ultrasound-guided biopsy product capacity during 2023, increasing outpatient diagnostic procedure efficiency by 24%.
• Argon Medical Devices introduced ergonomic spring-loaded biopsy technology in 2024 that improved physician handling precision by 18% during targeted procedures.
• Invivo launched an AI-integrated biopsy imaging synchronization system during 2025 that improved MRI fusion-guided lesion localization accuracy by 31%.

Report Coverage of Prostate Biopsy Needle Market

The Prostate Biopsy Needle Market report provides comprehensive analysis of biopsy technologies, urology diagnostic procedures, healthcare applications, competitive landscape, and regional adoption trends. The report evaluates reusable and disposable biopsy systems, MRI-guided diagnostics, ultrasound-compatible biopsy devices, and robotic-assisted biopsy technologies across global healthcare markets.

The study includes segmentation analysis by device type and healthcare application. Disposable biopsy devices dominated with 64% market share due to strong infection prevention requirements, while hospitals represented 58% of total procedures globally. Ambulatory surgical centers contributed 23% because minimally invasive outpatient diagnostics expanded significantly during 2025.